Skip to content

Folic Acid vs 5-methyltetrahydrofolate (5MTHF) in Recurrent Abortion

Comparison of the Effect of Folic Acid and 5-methyltetrahydrofolate (5MTHF) on Serum Folate and Homocysteine Levels, and Abortion Rates in Women Suffering From Recurrent Abortion

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01976676
Enrollment
220
Registered
2013-11-06
Start date
2011-04-30
Completion date
2014-09-30
Last updated
2015-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Abortion

Brief summary

Recent data indicates that 5 methyltetrahydrofolate (5MTHF) can reduce serum homocystein level more efficiently than folic acid. On the other hand, folic acid is currently an important part of treatment in idiopathic recurrent abortion. There is no study comparing the effectiveness of these supplements in the treatment of recurrent abortion. The aim of this study is to compare the efficiency of these two agents in the treatment of recurrent abortion. In this study, patients with idiopathic recurrent abortion, referring to Avicenna clinic will be randomly allocated into two groups of those taking either folic acid (5 mg) or 5 MTHF (5mg) from 8 weeks prior to conception until the 20th week of pregnancy. The serum level of folate, homocystein, and ongoing pregnancy will be analysed and compared in the two groups.

Interventions

DIETARY_SUPPLEMENT5-methyltetrahydrofolate
DIETARY_SUPPLEMENTfolic Acid

Sponsors

National Nutrition and Food Technology Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Willing to participate in the study and filling out the informed consent form, * History of 3 or more idiopathic abortion, * the last abortion should be more than 6 months ago, * no history of consumption of folate supplements or high folate containing foods during last 6 months, * All previous abortions should be idiopathic without any anatomic, cytologic, hormonal, septic pathologic finding, * no special diets

Exclusion criteria

* elective or induced abortion, molar or ectopic pregnancies, * presence of any malignancy, chromosomal abnormality, uterine abnormality, Thyroid, kidney, or liver dysfunction, Glucose intolerance, seizure, * Alcohol or drug abuse, * Taking any drug affecting homocystein metabolism, * not following the study protocol.

Design outcomes

Primary

MeasureTime frame
ongoing pregnancy on the 20th week of gestational age20th week of gestational age

Secondary

MeasureTime frame
serum concentration of folateat the weeks 0 and 8 of the study, and weeks of 4, 8, 12, and 20th gestational age
Serum concentration of Homocysteinat the weeks 0 and 8 of the study, and weeks of 4, 8, 12, and 20th gestational age

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026